Recursion Pharmaceuticals, Inc. (BMV:RXRX)
Mexico flag Mexico · Delayed Price · Currency is MXN
100.70
-5.30 (-5.00%)
At close: Jul 14, 2025

Recursion Pharmaceuticals Company Description

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States.

The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited.

Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Recursion Pharmaceuticals, Inc.
CountryUnited States
Founded2013
IndustryBiological Products, Except Diagnostic Substances
Employees800
CEOChristopher Gibson

Contact Details

Address:
41 South Rio Grande Street
Salt Lake City, Delaware 84101
United States
Phone385 269 0203
Websiterecursion.com

Stock Details

Ticker SymbolRXRX
ExchangeMexican Stock Exchange
Stock TypeCommon Stock
Share ClassClass A Shares
Fiscal YearJanuary - December
Reporting CurrencyUSD
SIC Code2836

Key Executives

NamePosition
Christopher GibsonChief Executive Officer
Ben TaylorChief Financial Officer
Kristen RushtonChief Operating Officer